The rise of modern oral nicotine products, such as nicotine pouches and lozenges, represents a significant shift in the tobacco harm reduction landscape. These tobacco-free alternatives are increasingly being adopted by adult consumers seeking safer nicotine delivery options. However, with their rapid growth, global regulatory bodies face the challenge of establishing robust frameworks that balance…
The global tobacco epidemic continues to present one of the most significant public health challenges, with over 7 million deaths annually attributed to tobacco use. As governments and health organizations grapple with this crisis, Tobacco Harm Reduction (THR) emerges as a pragmatic and scientifically supported strategy to mitigate the adverse health effects of smoking for…
We are thrilled to announce the appointment of Phil Hudson as the newest member of the GINN team. Phil will spearhead membership and outreach initiatives across the UK and European markets, bringing a wealth of experience and insight to our mission of advancing tobacco harm reduction and fostering innovation in the novel nicotine industry. A…
The U.S. Food and Drug Administration (FDA) has taken a landmark step in tobacco harm reduction by authorizing the marketing of 20 ZYN nicotine pouch products. This authorization, granted under the Premarket Tobacco Product Application (PMTA) process, establishes a clear regulatory pathway for nicotine pouches, reinforcing their role as a viable alternative for adult smokers…
The growing popularity of nicotine pouches as a smoke-free alternative has positioned them as a pivotal tool in tobacco harm reduction. However, their rapid market growth has also drawn increased regulatory scrutiny, particularly in the European Union (EU). As policymakers deliberate over the future of these products, the question arises: Could nicotine pouches face stricter…
In the evolving landscape of tobacco harm reduction, understanding the factors that influence consumer behavior is critical. Behavioral research plays a pivotal role in shaping strategies to encourage the adoption of reduced-risk products, fostering informed decision-making, and advancing public health objectives. By integrating data-driven insights, researchers and policymakers can better address the complexities of nicotine…
The rise of nicotine pouch use in Great Britain, while modest, signals a pivotal shift in tobacco consumption trends. According to a new study published in Nicotine and Tobacco Research by Dr. Leonie Brose, Laura Bunce, and Hazel Cheeseman, nicotine pouch usage has reached 5.4%. However, only 1% of respondents reported current use, suggesting that…
Independent nicotine pouch manufacturers distinguish themselves from Big Tobacco by focusing exclusively on smoke-free alternatives. Unlike larger companies tied to cigarette sales, their business model is free from conflicts of interest, allowing them to fully commit to harm reduction. This enables innovation in product safety, technology, and consumer satisfaction, which are key to fostering trust…
Maintaining credibility and integrity through independence from industry influence is a cornerstone of GINN’s mission. We are committed to fostering a transparent and independent relationship with stakeholders, especially public health professionals. To uphold this commitment, GINN does not accept funding from transnational or multinational tobacco companies. GINN welcomes smokeless tobacco companies, but those involved in…
How-To Guides Step-by-Step Instructions for Each Product Nicotine Pouches: Nicotine Strips: Nicotine Lozenges: Nicotine Gum: Heat Not Burn Systems: Dissolvable Nicotine Products: Potential Side Effects Best Practices FAQs What nicotine level should I choose? Can I use nicotine products with other medications? How long should I use nicotine alternatives? Are these products safe during pregnancy?…
